Across 27 studies and 13,724 women who froze their eggs, about 11 in 100 ever came back for them — and fewer than 3 in 10 of those had a baby. Everything else about egg freezing follows from that one number.

On a Sunday livestream, a member of Congress pointed a fertility injection at her own belly and told her followers not to be weird about it. “don’t be weird about this,” she said.

They were weird about it.

Within two days the conversation had moved from her eggs to her breakup, her politics, and whether she was selling other women a fantasy about having it all.

Her private life is not my business.

What she was told before the needle went in is, and so is what the millions of women watching now believe about egg freezing.

That is not politics.

It is a medical question with numbers attached, and the numbers are not the ones in the advertising.

Begin with what the procedure is.

For ten to twelve days a woman injects hormones so that many eggs mature at once instead of the single egg her body would release on its own.

The eggs are collected under sedation, and the mature ones are flash-frozen in liquid nitrogen and stored.

That is all of it.

An egg is not an embryo, and an embryo is not a baby. About eight in ten eggs survive thawing. Of those, some fertilize. Of those, some become usable embryos. Of those, some implant.

Every step subtracts.

Now the numbers that rarely appear on a clinic homepage.

The largest review to date pooled 27 studies and 13,724 women who froze eggs to delay childbearing, with a median follow-up of seven years. Just under 11 in every 100 came back to thaw them. Of the few who returned, 29 in 100 had a baby. A long-running New York cohort followed women who froze between 2005 and 2009 for ten to fifteen years, long enough for a final answer: 38 in 100 used their eggs and 59 in 100 never did. That is the highest return rate published anywhere, and it is still fewer than four women in ten.

When women do come back, the eggs work better than the pessimists claim.

Among 543 women who thawed at that center, 39 in 100 ended up with a baby, and more than half succeeded if they had been under 38 at freezing or thawed at least 20 mature eggs. A widely used counseling model puts 20 mature eggs frozen at 34 at roughly a 90 percent chance of a live birth, about 75 percent at 37, and about 37 percent at 42. That model came from laboratory data rather than from women who returned, as its authors said plainly, and real outcomes run below modeled ones. The shape still holds, and it is the point: age at freezing is the whole ballgame.

The strongest argument against my position deserves a hearing: egg freezing is undersold, not oversold.

In a 2025 survey of 260 women who had frozen eggs, the typical woman guessed her chance of a baby at 50 percent when the model put it at 75. Regret runs opposite to what critics assume — in a study of 173 women, 9 percent regretted freezing and 51 percent regretted not doing it. Those findings are real. But the comparison number is a model, not a birth, and regret was measured six months out, years before anyone learns whether the eggs work. Fear of missing the window is easy to capture early. Disappointment arrives a decade later, quietly, in a different clinic.

Then there is what freezing does not preserve.

Freezing an egg at 35 does not freeze the woman around it. If she returns at 44 she is pregnant at 44, with the higher rates of high blood pressure, diabetes in pregnancy, cesarean delivery and stillbirth that come with pregnancy after 35 and climb steeply after 40.

And there is money, which deserves its own paragraph because clinics almost never put it in one.

The figures below come from clinic and market price lists rather than peer-reviewed cost studies, and they vary by region. Up front, the procedure itself — monitoring, retrieval, freezing — runs about $8,000 to $15,000 for one cycle. The hormone injections are usually billed separately by the pharmacy and add roughly $3,000 to $7,000. All in, one cycle lands near $12,000 to $20,000, and most women need two, so the realistic entry price is about $24,000 to $36,000. Then the meter starts. Storage runs about $500 to $1,000 a year at most clinics, higher in the big cities and lower at off-site cryobanks: call it $40 to $85 every month, roughly a phone bill, for as long as the eggs sit there. Ten years of that is another $5,000 to $10,000. And the thaw itself — warming, fertilization, embryo culture, genetic testing, transfer — is a separate bill years later, closer to a full round of in vitro fertilization than to a retrieval. With an 11 percent return rate, most women pay the entry price and the monthly fee for a decade and use none of it.

This is where the ethics live, and they are not complicated.

The 2024 ethics opinion of the American Society for Reproductive Medicine says planned oocyte cryopreservation is permissible, that patients should be told the benefits are uncertain, and that providers should disclose their own center’s freeze-thaw and live-birth results — or admit they have none.

That is exactly right and almost nowhere honored. Count the clinic pages that open with “peace of mind” and “take control of your future,” then count the ones that open with their own thaw-to-birth rate. The distance between them is the consent failure.

I part company here with the profession’s favorite hiding place, which is choice.

Handing a woman a menu is not counseling her.

Three numbers belong in the first conversation, before any deposit: her chance of a live birth at her age with the number of eggs this center actually retrieves, her chance of never using them at all, and the full cost including the thaw and transfer years later. A clinician who leaves those out has not respected her autonomy. He has handed her a brochure and called it consent.

Behind the small abandonment sits a larger one.

When an employer pays for egg freezing but not for childcare, paid leave, or a career that survives having a child at 30, a structural problem has been relocated into a woman’s ovaries.

That is cheaper for the employer. It is not cheaper for her.

My position is this.

Egg freezing is a real technology with a modest, steeply age-dependent yield, and it is not insurance.

It belongs in a conversation in the early thirties rather than the late thirties, with enough eggs banked to matter, and with the return rate in the first sentence rather than the fifth.

I would tell any woman considering it what I would want told to my own granddaughter: frozen eggs are a chance, not a plan; the chance at 32 is far better than the chance at 38; and the most valuable thing a clinic can give her is not the freezing but the truth about her own numbers, early enough that she still has choices. Whether she freezes her eggs is nobody’s verdict on her ambition. Whether she was told the truth first is a professional obligation, and we are failing it.

If you know someone deciding this right now, send her the return rate before she sends anyone a deposit. ObGyn Intelligence is free because the evidence should travel. A paid subscription keeps it independent.

References

1. Kirubarajan A, Patel P, Thangavelu N, Salim S, Sadeghi Y, Yeretsian T, et al. Return rates and pregnancy outcomes after oocyte preservation for planned fertility delay: a systematic review and meta-analysis. Fertil Steril. 2024;122(5):902-17. doi:10.1016/j.fertnstert.2024.06.025

2. Blakemore JK, Grifo JA, DeVore SM, Hodes-Wertz B, Berkeley AS. Planned oocyte cryopreservation—10-15-year follow-up: return rates and cycle outcomes. Fertil Steril. 2021;115(6):1511-20. doi:10.1016/j.fertnstert.2021.01.011

3. Cascante SD, Blakemore JK, DeVore S, Hodes-Wertz B, Fino ME, Berkeley AS, et al. Fifteen years of autologous oocyte thaw outcomes from a large university-based fertility center. Fertil Steril. 2022;118(1):158-66.

4. Goldman RH, Racowsky C, Farland LV, Munné S, Ribustello L, Fox JH. Predicting the likelihood of live birth for elective oocyte cryopreservation: a counseling tool for physicians and patients. Hum Reprod. 2017;32(4):853-9. doi:10.1093/humrep/dex008

5. Friedman M, Jaffe N, Tairy D, Torem M, Raziel A, Finkelstein M, et al. Do women accurately predict their odds of having a child following planned oocyte cryopreservation? Reprod Fertil. 2025. doi:10.1530/RAF-24-0118

6. Jaswa EG, Pasch LA, McGough A, Wong R, Corley J, Cedars MI, et al. Decision regret among women considering planned oocyte cryopreservation: a prospective cohort study. J Assist Reprod Genet. 2023;40(6):1281-90. doi:10.1007/s10815-023-02789-w

7. Ethics Committee of the American Society for Reproductive Medicine. Planned oocyte cryopreservation to preserve future reproductive potential: an Ethics Committee opinion. Fertil Steril. 2024;121(4):604-12. doi:10.1016/j.fertnstert.2023.12.030

8. American College of Obstetricians and Gynecologists. Pregnancy at age 35 years or older. Obstetric Care Consensus No. 11. Obstet Gynecol. 2022;140(2):348-66. doi:10.1097/AOG.0000000000004873

9. Karni A. With big choices ahead, Ocasio-Cortez navigates new territory. The New York Times. 2026 Aug 12.

Note on costs: the price ranges in the text come from clinic and market price lists, not from peer-reviewed cost analyses, and vary widely by region.

In Vitro Fertilization (IVF) is a medical marvel that has brought immense joy to countless families. Yet, the public narrative often simplifies it to a single, miraculous procedure. As an obstetrician, an ethicist, and a professor, I believe patients deserve a more comprehensive, candid guide to the realities of IVF. This is a complex, emotionally taxing, and financially burdensome process that begins long before a fertilized egg is transferred. It is a journey that requires not just medical intervention, but a profound commitment from both partners.

The Foundations: Learning the Basics of Fertility

Before considering IVF, a couple must understand the fundamentals of their own fertility. The rush to high-tech solutions often bypasses a thorough investigation of the basics, which can sometimes reveal simpler, less invasive paths to parenthood.

For patients: You and your partner should first understand your individual fertility profiles. This includes tracking ovulation cycles, understanding hormonal fluctuations, and recognizing potential signs of underlying issues. Knowledge is your first and most powerful tool.

For providers: It is our ethical duty to ensure a couple has exhausted all less invasive options before recommending IVF. This includes a full fertility workup, which can involve hormone testing, ovulation tracking, and a comprehensive semen analysis.

The Whole-Body Approach: Weight, Diet, and Sperm Health

A crucial, yet often under-emphasized, part of the IVF journey is optimizing the health of both partners. IVF is not a substitute for a healthy body; it is a procedure that is most successful when used in conjunction with a healthy lifestyle.

For patients: Your weight and diet can profoundly impact the success of IVF. If you are overweight or obese, losing even 5-10% of your body weight can significantly improve ovarian response and pregnancy rates. This also applies to the male partner, as a healthy diet and optimal weight are directly linked to sperm quality and motility. You should both work towards a balanced diet rich in antioxidants, lean proteins, and healthy fats.

For providers: We have an ethical obligation to discuss these lifestyle changes with our patients. Frame this not as a criticism, but as a critical part of a successful treatment plan. Providing resources for nutritional counseling and weight management is a key component of comprehensive care.

Do You Really Need IVF? The Quest for a Definitive Diagnosis

The question "Do we really need IVF?" is one that every patient should ask and every provider should be prepared to answer with absolute honesty. There are often other, less drastic ways to find the "absolute reason" for infertility.

For patients: Demand a full diagnostic workup to pinpoint the exact cause of infertility. This should include a hysterosalpingogram (HSG) to check for blocked fallopian tubes, advanced hormonal panels (FSH, LH, AMH), and a detailed, multi-parameter semen analysis. Do not accept a generic "unexplained infertility" diagnosis without a thorough investigation.

For providers: The ethical imperative is to conduct a complete diagnostic journey before recommending IVF. A patient should never feel they are being rushed to a procedure without a clear understanding of the underlying cause. IVF is not a one-size-fits-all solution, and for many couples, the problem may be surgically correctable or responsive to simpler therapies.

The Financial and Emotional Toll of IVF

IVF is a grueling process, not just physically, but financially and emotionally. The costs can be staggering, often reaching tens of thousands of dollars per cycle, and a single cycle is rarely enough. These financial pressures, combined with the emotional rollercoaster of hope and disappointment, can strain even the strongest relationships.

For patients: Be prepared for the emotional and financial realities. The journey can feel like a part-time job, with frequent clinic visits, injections, and blood draws. Seek emotional support from therapists or support groups that specialize in infertility.

For providers: We must be transparent about the financial burdens and emotional complexities of IVF. Discuss the need for multiple cycles, potential out-of-pocket costs, and the importance of mental health support.

A High-Risk Journey: IVF Pregnancies Are Not All the Same

What is often not told to patients is that an IVF pregnancy, by its very nature, is automatically considered high-risk. This is not to cause alarm, but to emphasize the need for heightened vigilance and specialized care.

For patients: Be prepared for a different level of care compared to a spontaneous pregnancy. You will likely have more frequent ultrasounds, doctor's appointments, and monitoring. This is a proactive measure to ensure the best possible outcome for you and your baby.

For providers: It is our ethical and clinical duty to classify all IVF pregnancies as high-risk from the outset. This ensures that the patient receives the specialized care they need, from a higher frequency of fetal monitoring to a more vigilant watch for complications such as preeclampsia and placental issues. A multidisciplinary team, including maternal-fetal medicine specialists and neonatologists, should be involved in the patient's care from the very beginning.

Potential Complications in IVF Pregnancies:

• Placental Abnormalities: There is a statistically higher risk of conditions such as placenta previa and placental abruption.

• Preeclampsia and Gestational Hypertension: The risk of these conditions is elevated in IVF pregnancies.

• Preterm Labor and Low Birth Weight: IVF pregnancies, particularly those with multiple gestations, have a higher risk of preterm birth.

• Chromosomal and Congenital Abnormalities: While not due to the IVF process itself, the underlying reasons for infertility can sometimes be associated with a slightly increased risk of certain conditions.

In conclusion, IVF is an incredible tool, but it is not a magic bullet. By providing patients with the full, unvarnished truth about the entire process—from the initial workup to the high-risk nature of the pregnancy itself—we can empower them to navigate this complex journey with knowledge and confidence. This is the essence of true obstetrical intelligence: a commitment to full transparency, grounded in academic rigor and profound compassion.

We throw bachelor parties, register for china, and plan the seating chart down to the cousin nobody likes. The one test that covers half of a couple’s future fertility never makes the list.

More than half of the difficulty couples have getting pregnant involves the man. In about 1 in 2 cases, a sperm problem is part of the picture, and in about 1 in 5 cases it is the whole picture.^{1 2} Despite this, the fertility workup almost always begins with the woman. She gets the bloodwork, the ultrasound, the timed cycles. He gets asked to wait.

Subscribe now

That order is backwards. The first fertility test a couple should do is a semen analysis, and the man can take the first version of it without leaving the house.

What a Semen Analysis Actually Tests

A semen analysis looks at a fresh sample under controlled conditions and reports several separate numbers. Each one answers a different question, and a couple should know what each means before reading a report.

Concentration is how many sperm are in each milliliter of fluid. Total sperm number is the count in the whole sample, which matters more than concentration alone because two men with the same concentration can have very different totals if their volumes differ.³

Share

Motility is the share of sperm that move. Progressive motility is the share that swim forward in a straight line, which is the part that counts, since sperm have to travel to reach the egg. Morphology is the share with a normal shape. Volume, vitality, and pH round out the report.

Here are the current World Health Organization sixth-edition lower normal values. These are not pass-or-fail lines. They are the fifth percentile of men who fathered a child within a year, so a number just below the cutoff does not mean a man cannot father a child.^{4 5}

Why the Man Should Go First

The reason to test the man first is simple arithmetic. A semen analysis is faster, cheaper, and far less invasive than the female workup, and it covers half the possible problem in one step.^{1 2} Skipping it does not protect anyone. It only delays an answer.

Most sperm problems cause no symptoms. A man can feel fine, have a normal sex life, and still have a low count or poor motility. ⁶ The only way to know is to look. And one survey found that fewer than half of obstetrician-gynecologists routinely considered evaluating the male partner before ordering tests on the woman.² That gap is exactly the kind of habit worth breaking.

Here is a reason to do this test now rather than later.

Telehealth has made testosterone easy to start with a few taps and a short video call, and prescriptions have climbed. What too many of these visits skip is the warning that testosterone is, in effect, a male contraceptive. When a man takes testosterone from outside the body, his brain reads the supply as sufficient and shuts down the signals that tell the testicles to make sperm. The result is predictable. In one large study, after six months of weekly testosterone injections, roughly two in three men had no sperm at all in the ejaculate, and the average time to reach that point was about 120 days.¹³ Other series put the share of testosterone users with a low or absent sperm count even higher.¹⁴

The effect is usually reversible, but recovery can take 6 to 12 months or longer after stopping, and a meaningful number of men never return to their starting count.¹³

This is why every man of reproductive age should have a baseline semen analysis before he starts testosterone, and one study found that fewer than 2 percent actually do.¹⁵

A man who wants children, now or someday, should know his number before the first dose, not after a year of trying.

The next part is the practical playbook: how the at-home test compares to the clinic test, exactly how each one is done, and the one rule that keeps a single bad result from sending you down the wrong path. Paid subscribers read on.

Read more

She drives home alone.

That scenario is not unusual. It is the standard. And it is where the AI empathy debate is most practically consequential, because the gap that appointment leaves is now being filled by chatbots that answer questions at midnight, validate feelings in real time, and provide more emotional acknowledgment than most women receive in the clinical encounter itself.

The research finding that patients rate AI responses as more empathic than physician responses is not surprising in this context. [1] What it reveals is a compassion deficit so large that a language model can step into it and be experienced as better care. That is not a compliment to the technology. It is an indictment of what miscarriage care has become.

Empathy Is Not Enough

• Empathy is the perception of another person’s emotional state and some resonance with it. A clinician who acknowledges that a miscarriage is painful is demonstrating empathy. So is a well-trained chatbot.

• Compassion goes further: it is the commitment to act on what you perceive, to be present to the specific person in front of you, and to stay in that presence through the parts that are hard.

Miscarriage affects approximately 10 to 20 percent of known pregnancies, with higher rates in women over 35.

The majority have no identifiable cause. That last fact is one of the hardest things in medicine to communicate compassionately. Compassion means sitting with a woman in the fact that there is no explanation, no culpability, and no clear path to preventing it next time, and not retreating into the biology in order to manage your own discomfort.

What patients report needing after miscarriage is not primarily information. Studies on miscarriage experience consistently find that women want to feel that their loss was acknowledged as a loss, that the clinical team understood what this pregnancy meant to them, and that they were not processed through a protocol. Those are not communication preferences. They are descriptions of what compassionate care looks like.

Free readers see above. Paid subscribers continue below. —

Read more

What Recurrent Pregnancy Loss Means, and Why the Number Keeps Changing

Recurrent pregnancy loss means more than one miscarriage in a person who is trying to have a baby. The hard part has always been the threshold. How many losses before a couple deserves testing instead of a shrug and the words try again? That number is not a law of nature. It is a choice, and the choice decides who gets care.

The direction across the major guidelines is clear. ASRM set the bar at two clinical losses in 2012 and kept two in its 2026 update, now counting biochemical, test-only losses and counting losses whether or not they happened back to back.^{1 2}

ESHRE moved to two losses in 2017 and held that line in its 2022 update.³

The Society of Obstetricians and Gynaecologists of Canada set two losses before 20 weeks in 2025.⁵

Only the RCOG still defines recurrent miscarriage as three or more first trimester losses, though it tells clinicians to investigate after two when something looks wrong.⁴

The Stakes: Who Gets Through the Gate

Why the threshold matters: fewer than 5 in 100 women experience two miscarriages, and only about 1 in 100 experience three or more.² Set the definition at three and you turn away most of the women who are frightened, grieving, and asking for help after a second loss. Set it at two and you let them in. The definition is not bookkeeping. It is a gate.

Cell entries are condensed from each guideline. Selective means reserved for specific clinical situations rather than offered to everyone.

The tables show where the world’s guidelines agree and where they split. What that means for your testing, your money, and your next pregnancy is below. Paid subscribers read on.

Read more

Day One: The Official Resource

The observers began where any responsible researcher begins: with the government. The United States of America maintains a website called moms.gov, operated by its Department of Health and Human Services and launched, with considerable ceremony, on the holiday this species has designated for honoring its maternal units.

The observers spent several hours with this resource. They took detailed notes.

According to moms.gov, human reproduction requires the following: a female who tracks her basal body temperature each morning before speaking or moving; a female who monitors changes in her cervical secretions across a 28-to-35-day cycle; a female who charts this data across eight to twelve months to establish her personal fertile window; a female who takes 400 micrograms of folic acid daily; a female who avoids alcohol, maintains a healthy weight, and manages stress.

The observers reviewed these instructions carefully. They cross-referenced them with their training in basic xenobiology.

Something appeared to be missing.

They searched the resource for any mention of the male of the species. They found references to the male in the context of emotional support during pregnancy. They did not find the male in the context of conception. The word sperm does not appear on moms.gov’s fertility guidance pages. The word semen does not appear. The phrase male factor does not appear.

Observer One filed the following preliminary note: “Human reproduction may be parthenogenic. Recommend further investigation before filing census report.”

Day Two: The Fertilization President

The observers were thorough. They did not stop at one source.

Further research revealed that the leader of this nation had, in February 2025, signed an executive order to expand access to a procedure called in vitro fertilization, or IVF. He had referred to himself, in public, as the “fertilization president.” The observers noted this title with interest. They hoped it would clarify the male’s role.

In October 2025, the fertilization president announced a landmark agreement with a pharmaceutical company called EMD Serono. The agreement would reduce the cost of three injectable medications — Gonal-F, Ovidrel, and Cetrotide — by 84% through a government platform called TrumpRx.gov. The president stood in his Oval Office. Officials stood beside him. The announcement was covered extensively.

The observers examined all three medications. Gonal-F stimulates the female’s ovaries to produce multiple eggs. Ovidrel triggers the final maturation of those eggs. Cetrotide prevents premature ovulation.

All three act exclusively on the female reproductive system.

The observers searched the TrumpRx platform for any medication addressing male reproductive function. They found none. They searched the executive order for any mention of sperm. They found none. They searched the associated press releases, the White House fact sheet, and the Labor Department guidance on employer fertility benefits.

Observer Two updated the preliminary note: “Fertilization president appears to be fertilization-adjacent. The male’s biological contribution remains unlocated in official documentation.”

Day Three: The $300 Question

On the third day, one of the observers made a discovery.

Buried in the National Library of Medicine’s database — not on moms.gov, not on TrumpRx.gov, not in the executive order, not in any document carrying a .gov domain that addressed fertility directly — was a description of a diagnostic test called a semen analysis.

The observers read it carefully.

A semen analysis evaluates the male’s reproductive contribution: sperm count, with a normal threshold of at least 15 million per milliliter; motility, with at least 40% of sperm required to move effectively; and morphology, with at least 4% required to be normally shaped. The test is non-invasive. It is conducted in a clinical laboratory. Results are typically returned within 24 to 48 hours. The cost, in the United States, is approximately $200 to $300.

The observers then consulted the peer-reviewed literature. They found that male factor is solely responsible for infertility in approximately 20% of couples and contributes to the problem in an additional 30% to 40%.(1,2) In total, male factor substantially contributes to approximately 50% of all cases in which human couples cannot conceive.(3)

Observer One sat quietly for a moment.

“So,” Observer One said, “for roughly half the couples who cannot reproduce, the answer may be findable with a $300 test that takes one appointment and requires no injections, no surgical procedures, and no ovarian stimulation.”

“That appears to be correct,” said Observer Two.

“And the government’s response was to discount the ovarian stimulation drugs.”

“Yes.”

“The drugs that cost $5,000 per cycle. That represent approximately 20% of the total cost of a treatment that runs $15,000 to $20,000.”

“Correct.”

Observer One made a note. Then crossed it out. Then made it again.

The Filed Report

The observers submitted the following findings to the Galactic Census Bureau:

Human reproduction is a two-gamete process requiring both a female egg and a male sperm cell. This is not in dispute in the scientific literature. It appears, however, to be in dispute in American fertility policy.

The official government resource for preconception guidance addresses the female reproductive cycle in considerable detail. It does not address the male reproductive contribution. It promotes fertility awareness-based methods as a primary strategy for couples who cannot conceive. A fertility awareness method tracks the woman’s ovulation. It does not evaluate sperm.

The national government has invested political capital in reducing the cost of medications that stimulate female ovarian function for IVF. IVF is an appropriate treatment for many causes of infertility. It is not the appropriate first step for a couple in which the male has a low sperm count, poor motility, or a varicocele — a surgically correctable condition present in up to 40% of men evaluated for male factor infertility, for which repair is often effective.(2) For these couples, IVF without a prior semen analysis is not a fertility treatment. It is an expensive procedure addressing the wrong partner.

We recommend that the species consider the following, in order: one semen analysis, before anything else. Its cost is $300. Its information content, for approximately half of infertile couples, is decisive.

We are returning to our home planet. We found the biology clear. The policy, less so.

The cervical mucus charts were especially confusing.

My Take

The satire is exact. Every number in this piece is real. Male factor contributes to 50% of infertility cases.(1,2,3) A semen analysis costs $200 to $300. The Trump administration’s fertility initiative discounts drugs that act exclusively on the female reproductive system. moms.gov does not mention sperm. None of this is a caricature. It is the policy, described accurately, through a frame that makes its absurdity visible.

I am not dismissing the IVF cost initiative. Reducing the cost of fertility medications is a real benefit for real patients. For couples who need IVF — and many do — an 84% discount on stimulation drugs is meaningful. I do not minimize that.

What I am saying is that fertility policy which begins with the woman and ends with the woman, without pausing to evaluate the man, will send roughly half its intended beneficiaries in the wrong direction. Some of them will undergo months of ovarian stimulation, egg retrieval, and embryo transfer before anyone thinks to order a semen analysis. Some of them will spend $20,000 on a cycle before anyone asks whether the problem was a varicocele that a urologist could have repaired for a fraction of that cost.

The semen analysis is the single most important test in the infertility workup. It is cheap, non-invasive, fast, and informative. Its absence from every government fertility resource launched in the past 12 months is not an oversight. It reflects a persistent cultural assumption — one this country’s fertility policy has apparently not examined — that infertility is a female problem.

It is not. It is a couple problem. Half the time, it is a male problem. The $300 test that establishes which half you are in should be the first thing any couple struggling to conceive is told to do. It should be on moms.gov. It should be in the executive order. It should be the first slide in any government presentation about helping Americans have babies.

The aliens were confused. They had good reason to be.

Bottom Line

A fertility policy that ignores male factor is not a fertility policy. It is a preconception program for women. Those are not the same thing, and couples who need to know the difference are currently being failed by every official resource their government has built.

If you want the complete picture of infertility — what causes it, how to evaluate it, and what the evidence says about when to seek help — ObGyn Intelligence covers it without the ideological filter. Subscribe below.

— Amos Grünebaum, MD / ObGyn Intelligence | obmd.com

References

1. Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015;13:37. doi: 10.1186/s12958-015-0032-1. PMID: 25928197.

2. Leslie SW, Siref LE, Khan MAB. Male Infertility. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 32965929.

3. Krausz C, Escamilla-Sanchez A. Male infertility. Lancet. 2021;397(10271):319-332. doi: 10.1016/S0140-6736(20)32667-2. PMID: [VERIFY].

4. American College of Obstetricians and Gynecologists. Evaluating Infertility [FAQ]. Washington (DC): ACOG; 2022. Available from: https://www.acog.org/womens-health/faqs/evaluating-infertility.

She left with a diagnosis and no plan.

That is a clinical failure, and it happens every day.

PCOS affects between 8% and 13% of women of reproductive age, making it the most common hormonal disorder in women. It is also one of the most mismanaged. The diagnosis is often handed out too loosely or, conversely, missed entirely. The next steps are rarely explained. And the window between diagnosis and the decision to conceive, which can span years, is almost never used well.

If you have been told you have PCOS and you want to have children someday, this post is for you.

Step One: Make Sure the Diagnosis Is Real

This matters more than most patients are told. PCOS is a diagnosis of exclusion. That means before anyone can properly say you have it, other conditions that look similar must be ruled out: thyroid disease, elevated prolactin, congenital adrenal hyperplasia, and androgen-secreting tumors, among others. Some of these carry serious implications of their own and need different treatment entirely.

The standard criteria for PCOS diagnosis are the Rotterdam criteria, updated and strengthened by international evidence-based guidelines in 2023.

You can use the PCOS Screener at tools.obmd.com/pcos-screener to work through the Rotterdam criteria yourself before your appointment.”

Under these criteria, you need at least two of the following three findings, with other causes excluded:

A critical point: having polycystic-looking ovaries on ultrasound alone does not mean you have PCOS. Up to 20% of women with completely normal cycles have ovaries that look polycystic on ultrasound. The word polycystic on your radiology report is not a diagnosis.

If your doctor made the diagnosis based only on an ultrasound or on irregular periods without checking your hormones and ruling out other causes, the diagnosis deserves a second look.

Which Doctor Should You See?

This depends on where you are in your journey.

If you are not trying to conceive in the next six months, a knowledgeable general obstetrician-gynecologist can absolutely manage your PCOS evaluation and initial treatment.

The priorities at this stage are confirming the diagnosis correctly, checking your metabolic health (fasting glucose, insulin, lipids, blood pressure), addressing symptoms like excess hair growth or acne, and starting lifestyle changes that will improve your hormonal environment before you ever need fertility treatment.

If you are planning to conceive within the next six months to a year, or if your cycles are so irregular that you have difficulty tracking ovulation at all, a referral to a reproductive endocrinologist and infertility specialist (REI) is reasonable.

An REI has the training and tools to assess your ovarian reserve, monitor ovulation induction cycles, and manage the full spectrum of PCOS-related fertility challenges.

You do not need to go directly to an REI. You do not need IVF as a first step. But you should not wait until you have been trying to conceive for a year before getting a proper evaluation, which is the standard advice given to women under 35. Women with known ovulatory dysfunction, which is what PCOS produces, should seek evaluation after six months of trying without success, or sooner if cycles are very irregular.

What You Can Do Right Now, Before You Are Ready to Try

The gap between PCOS diagnosis and fertility treatment is not dead time. It is the most powerful window you have. Here is what the evidence supports:

Weight and Metabolic Health

If your BMI is above 25 kg/m, losing 5% to 10% of your body weight through diet and exercise has been shown to restore ovulatory cycles, reduce testosterone levels, and improve insulin sensitivity. A structured 20-week exercise program in one systematic review improved ovulation rates by 49%. These are not small effects. Lifestyle change is not a consolation prize while you wait for medication. For overweight women with PCOS, it is the most powerful first intervention available.

If your weight is already in a healthy range, structured aerobic and resistance exercise still improves insulin sensitivity and androgen levels. The mechanism matters regardless of weight: PCOS is fundamentally tied to insulin resistance, which disrupts the hormonal signals that control ovulation.

Folic Acid and Preconception Nutrients

Start 400-800 micrograms of folic acid daily now. If you have a family history of neural tube defects or are taking certain medications, your doctor may recommend 4 milligrams daily instead. This is straightforward, inexpensive, and evidence-based. Do not wait until you get a positive pregnancy test to start.

Subscribe now

Track Your Cycles

Irregular cycles in PCOS mean that ovulation is unpredictable, not that it never happens. Tracking with basal body temperature, ovulation predictor kits, or a period tracking app gives you and your doctor real data. If you are ovulating occasionally, that information changes your management. If you are not ovulating at all, that information also changes your management.

Metformin

Metformin is an insulin-sensitizing medication that has been used in PCOS for decades. The 2023 international guidelines support its use to improve menstrual regularity, reduce androgen levels, and lower the risk of gestational diabetes during a future pregnancy. It is not a fertility drug by itself, but it improves the hormonal environment and can help restore more regular cycles in women with insulin resistance. Ask your doctor whether metformin makes sense for you now, before you need fertility treatment.

When You Are Ready to Try: What Fertility Treatment Looks Like for PCOS

PCOS is the leading cause of anovulatory infertility.

Anovulatory means you are not releasing eggs regularly.

The good news: anovulatory infertility responds well to treatment. Most women with PCOS who want to conceive do so, often without IVF.

The treatment ladder for PCOS-related infertility, as established by the 2023 international guidelines, looks like this:

1. Lifestyle modification first, in women with a BMI above 25 kg/m

2. Letrozole (an aromatase inhibitor) as first-line oral ovulation induction

3. Clomiphene with or without metformin as second-line oral therapy

4. Gonadotropins (injectable hormones) or ovarian drilling surgery as second-line procedures

5. IVF as third-line therapy, when other approaches have failed or there is another indication for IVF

Subscribe now

The NEJM landmark trial by Legro and colleagues (2014) established letrozole as superior to clomiphene for ovulation induction in PCOS. In that randomized controlled trial of 750 women, letrozole produced a cumulative live birth rate of 28% compared to 19% with clomiphene over five treatment cycles. Letrozole also carried a lower rate of twin pregnancies (3% versus 7%). If your doctor is still recommending clomiphene as the first choice, that recommendation is behind the evidence by a decade.

IVF is not a first step. It is expensive, physically demanding, and carries risks. The 2023 international guidelines are explicit: IVF should be offered only when other ovulation induction therapies have failed or when there is a separate reason IVF is needed. Women with PCOS who do go to IVF should receive single embryo transfer given the underlying pregnancy risks PCOS carries, including gestational diabetes, preeclampsia, and preterm birth.

One More Thing Most Doctors Do Not Mention

A fertility evaluation is never just about you. Before any treatment starts, your partner’s semen analysis should be done. About one in three cases of infertility involves a male factor. Starting ovulation induction without checking sperm first is putting the cart before the horse. Insist on this evaluation early.

My Take

A PCOS diagnosis handed over without a management plan is a missed opportunity. The years between diagnosis and a decision to conceive are not empty time. They are your best chance to improve your hormonal environment, protect your metabolic health, and position yourself for the simplest fertility path possible.

You do not need an REI on day one.

You need a clinician who will confirm the diagnosis properly, rule out other causes, check your metabolic numbers, and have an honest conversation about what your cycles are actually doing.

If that conversation does not happen, find someone who will have it.

When you are ready to conceive, letrozole is where the evidence points. Lifestyle change before that is not optional noise. It is the intervention with the best safety profile and no cost. And IVF, despite what fertility clinic marketing sometimes implies, is not the default destination for PCOS. For most women, it is not the destination at all.

Know your diagnosis. Know your numbers. And do not accept a pamphlet as a plan.

References

1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. doi: 10.1210/clinem/dgad463

2. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. N Engl J Med. 2014;371(2):119-129. doi: 10.1056/NEJMoa1313517

3. Jalilian A, Kiani F, Sayehmiri F, Sayehmiri K, Khodaee Z, Akbari M. Prevalence of polycystic ovary syndrome and its associated complications in Iranian women: A meta-analysis. Iran J Reprod Med. 2015;13(10):591-604. [VERIFY for exact global prevalence figure]

4. Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687-708. doi: 10.1093/humupd/dmw025

5. Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;3(3):CD007506. doi: 10.1002/14651858.CD007506.pub4

6. Deng Z, Hu X, Li P, You Y, Zhong X, Guo C. Impact of lifestyle interventions on reproductive and psychological outcomes in women with polycystic ovary syndrome. Medicine (Baltimore). 2025. doi: 10.1097/MD.0000000000041247

7. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41. doi: 10.1186/1741-7015-8-41

In Vitro Fertilization (IVF) is a testament to modern medical ingenuity, a procedure that has enabled countless couples to build the families they so deeply desire. The public narrative, however, often simplifies this journey, focusing solely on the celebratory outcome. As an obstetrician, an ethicist, and a professor, it is my professional and ethical …

Read more

Years later, laparoscopy reveals extensive endometriosis. She conceives shortly after surgery. The infert…

Read more

She had spent $400 a month on supplements.

CoQ10. Myo-inositol. Ashwagandha. DHEA. Omega-3s. A “fertility blend” with 23 ingredients she could not pronounce. Her Instagram feed was a scroll of pastel-branded promises. Her medicine cabinet looked like a small pharmacy.

She was 34. She and her husband had been trying for 14 months. She had never had a single conversation with a doctor about her weight, his weight, their diet, or how much they were actually exercising. Nobody had told her that the soda she drank every afternoon was more studied than anything in her supplement stack.

She had done everything the internet told her to do. And almost none of it was supported by the kind of evidence that would survive a peer-reviewed journal.

The Gap Between Wellness Culture and Reproductive Science

The global fertility supplement market reached $2.7 billion in 2025 (1). It is projected to nearly double by 2034. An analysis of male fertility supplements found that only 22% of the 90 ingredients tested showed any evidence of affecting sperm health or birth rates. The average product effectiveness score was 1.66 out of 5.0 (2).

Meanwhile, interventions with strong evidence often cost nothing. Moderate exercise improves fecundability. A Mediterranean-style diet is linked to better embryo quality. Folic acid, at roughly seven cents a day, carries the strongest recommendation in all of reproductive medicine.

The fertility industry sells complexity when the evidence supports simplicity.

What We Actually Know About Fertility and Lifestyle

Research on lifestyle and fertility comes primarily from large prospective preconception cohort studies. These are not small supplement trials with surrogate endpoints. They are studies of thousands of real couples tracking real pregnancies over real time.

Two of the most important are the PRESTO study (Pregnancy Study Online, North America) and SnartForaeldre.dk (Denmark). Together, they have followed more than 15,000 couples trying to conceive (3, 4). A 2024 prospective cohort from Rotterdam studied more than 3,600 women and their partners from preconception through birth (5).

These studies measure fecundability: the probability of conceiving in a given menstrual cycle. It is one of the most reliable metrics we have for fertility research. A fecundability ratio (FR) below 1.0 means you are less likely to conceive per cycle compared to the reference group.

Here is what the data tells us about what actually matters.

This is where it gets specific. The 7 things that are hurting your fertility and the 3 that actually help are below.

Read more

Sarah and David had been trying for 14 months. Their doctor said “infertility” and referred them straight to an IVF clinic. Nobody checked David’s sperm. Nobody asked about Sarah’s cycles. Nobody mentioned that David’s BMI was 34 or that Sarah had irregular periods every 40 to 45 days.

Eight months and $22,000 later, their IVF cycle failed. A second opinion revealed David had a varicocele and Sarah had PCOS. After varicocele repair, weight loss coaching for David, and ovulation induction for Sarah, they conceived without IVF.

This story is not unusual. And the reason it keeps happening is that too many couples skip the most important part of the fertility journey: finding out why.

What “Infertility” Actually Means

Let’s start with the basics. Infertility is defined as failure to achieve pregnancy after 12 months of regular, unprotected intercourse. For women over 35, that window shortens to 6 months. For women over 40, evaluation should begin immediately.

But here’s what most people don’t realize: infertility is not a diagnosis. It’s a description. Saying you have “infertility” is like saying you have “pain.” It tells you something is wrong. It tells you nothing about what or why.

The real work, the work that determines whether you spend years and tens of thousands of dollars on treatments that may not address your actual problem, begins with a proper evaluation. And that evaluation must include both partners from the start.

The Evaluation: Both Partners, at the Same Time

This is one of the most important things I can tell you. The 2024 AUA/ASRM guideline is explicit: clinicians should initiate concurrent assessment of both the male and female partner. Not “evaluate the woman first and then maybe check the man.” Both. Together. From the beginning.

Why? Because male factors contribute to infertility in roughly half of all couples. The ACOG Infertility Workup clinical practice guideline states that male factor is a cause of infertility in 40 to 50% of couples. Skipping the male evaluation doesn’t just waste time. It can lead to unnecessary, invasive, and expensive treatment of the female partner for a problem that originates with the male partner.

Subscribe now

Read more

When you’re diagnosed with difficulty getting pregnant, the number of acronyms thrown at you can feel like learning a new language under pressure. IVF. ICSI. IUI. TESE. FET. Your doctor may recommend one of these on your first visit, and you may have no idea what it actually involves, how it compares to alternatives, or whether simpler options exist.

Thi…

Read more

Lisa and her husband James had been trying to conceive for 10 months when they went down the internet rabbit hole. Within a week, James had thrown out his boxer briefs, quit coffee entirely, stopped going to the gym, and was eating handfuls of zinc supplements. Lisa had cut out gluten, dairy, sugar, alcohol, caffeine, and anything that came in plastic packaging. She was also sleeping with her legs elevated after sex because a TikTok told her to.

Neither of them was sleeping well. Both were miserable. And none of what they were doing was based on solid evidence.

This is what happens when anxious people meet an unregulated wellness industry. You get fear dressed up as empowerment. You get expensive supplements marketed with cherry-picked data. You get extreme restrictions that add stress to an already stressful situation, sometimes making things worse rather than better.

Here’s what the actual science says.

What This Guide Is and Isn’t

This is a summary of lifestyle factors with credible evidence for affecting fertility in men, women, or both. I’ve included what the research shows, how strong the evidence is, and what a reasonable response looks like.

This is not a promise that lifestyle changes alone will get you pregnant. For many couples, the cause of infertility is structural, genetic, or hormonal, and no amount of clean eating or boxers-over-briefs will fix it. Lifestyle optimization is one piece of the puzzle. Sometimes it’s the most important piece. Sometimes it’s irrelevant to your specific situation.

The point is to know the difference.

First Things First: Have Sex. The Right Amount. Forget Everything Else You’ve Heard.

The evidence: Strong. ASRM committee opinion level. Applies to timing, frequency, position, orgasm, and post-sex routines.

Before we talk about what you eat, drink, or breathe, let’s talk about the thing that actually makes babies. You would be surprised how many couples trying to conceive are confused about the basics, not because they’re uninformed, but because the internet has buried straightforward biology under layers of myths, gadgets, and monetized anxiety.

Subscribe now

Read more

“Women Deserve Data, Not Dogma.” This slogan captures everything that evidence-based medicine should stand for - and everything that’s gone wrong in how health information reaches women today. From fertility influencers hawking unproven supplements to wellness gurus promising that the right diet will “balance your hormones,” women trying to conceive are drowning in confident-sounding advice that prioritizes ideology over evidence. The fertility industry has learned that hope sells, and that “natural solutions” sound better than hard truths. But feelings aren’t facts, and validation isn’t the same as information. Here are the facts - not fads - that every woman trying to conceive deserves to hear.

Subscribe now

Read more

What is being discussed, plainly stated

Restorative Reproductive Medicine, often marketed as “natural” fertility care, is a set of approaches that claims to treat infertility by fixing underlying problems rather than using assisted reproductive technology such as IVF. A recent JAMA Viewpoint argues that this framing is misleading and, more importantly, harmful when it is used to restrict access to proven care.

A promise that sounds good, but falls apart

Read more

First clinical pregnancy following AI-based microfluidic sperm detection and recovery in non-obstructive azoospermia, published in The Lancet, November 2025.

Azoospermia is a condition in which no sperm are detected in the ejaculate on standard semen analysis. It can result either from failure of sperm production in the testes or from blockage that prevents sperm from reaching the ejaculate.

Read more

New research reveals that ultra-processed food can trigger addiction-like brain changes, especially in women, threatening fertility and pregnancy. It’s time to treat it like the public health crisis it is.

When a patient tells me she’s “trying to eat better” before getting pregnant, I often ask what that means. She might say she’s cut back on soda or switched from chips to protein bars. But here’s the unsettling truth: both are ultra-processed foods—and growing evidence suggests that these products don’t just fuel obesity. They may act on the brain much like addictive drugs, altering appetite control and hormonal balance in ways that threaten fertility and long-term health.

What Are Ultra-Processed Foods?

Ultra-processed foods (UPFs) are industrially manufactured products containing ingredients that don’t exist in any kitchen pantry—refined starches, added sugars, industrial fats, flavor enhancers, and emulsifiers.

Subscribe now

They’re designed for convenience, long shelf life, and “bliss point” pleasure. Think of sodas, flavored yogurts, breakfast cereals, sweetened coffee drinks, chips, energy bars, pizza pockets, chicken nuggets, or “low-fat” diet cookies.

Although they look like food, they behave more like a chemical formula engineered to keep you reaching for more. Research from the University of Michigan, published in Addiction (2025), shows that these products stimulate reward centers in the brain through combinations of refined carbohydrates and fats that mirror the neurochemical effects of nicotine or alcohol.

Here’s a more complete list of typical ultra-processed foods (UPFs) — the kind most associated with addiction-like eating and negative effects on fertility, metabolism, and pregnancy outcomes:

If it comes in a box, bag, or bottle with more than five ingredients—especially ones you wouldn’t cook with at home (maltodextrin, emulsifiers, colorings, hydrogenated oils, or flavorings)—it’s almost certainly ultra-processed.

Sugary and Sweetened Foods

• Candy, chocolate bars, gummies

• Packaged cookies, pastries, donuts, muffins

• Sweetened breakfast cereals (e.g., Froot Loops, Frosted Flakes)

• Ice cream and frozen desserts

• Protein bars, “energy” bars, and granola bars

• Flavored yogurts and pudding cups

• Syrups and sweetened spreads (e.g., Nutella, pancake syrup)

• Artificially sweetened “diet” desserts

Drinks

• Sodas, sports drinks, and energy drinks

• Sweetened iced teas and lemonades

• Flavored coffee beverages (frappuccino-type drinks)

• Powdered drink mixes and meal-replacement shakes

• Packaged fruit juices or “juice drinks” (with added sugar)

• Flavored waters and sparkling beverages with artificial sweeteners

Savory Snacks

• Potato chips, corn chips, cheese puffs

• Pretzels and flavored snack mixes

• Microwave popcorn with artificial butter

• Crackers made with refined flour, vegetable oil, and flavor enhancers

Fast Foods and Ready-to-Eat Meals

• Burgers, fried chicken sandwiches, chicken nuggets

• French fries and onion rings

• Frozen pizzas, burritos, and “TV dinners”

• Instant noodles, ramen cups, and boxed mac-and-cheese

• Processed lunch meats, hot dogs, sausages, and deli slices

• Pre-made wraps or sandwiches from convenience stores

“Diet,” “Low-Fat,” or “High-Protein” Processed Foods

• Low-fat cookies, rice cakes, or “100-calorie” snack packs

• Artificial sweeteners and sugar-free candies

• Meal-replacement shakes or bars

• Ready-to-drink protein beverages

Bakery and Breakfast Items

• Packaged bagels, waffles, pancakes, and toaster pastries (e.g., Pop-Tarts)

• Instant oatmeal packets with flavoring

• Flavored coffee creamers

Condiments and Flavor Enhancers

• Ketchup, mayonnaise, and salad dressings with added sugar or emulsifiers

• Instant sauces, gravies, seasoning packets

• Processed cheese spreads and “cheese-flavored” snacks

• Margarine and vegetable shortening

Infant and Family Convenience Foods

• Sweetened baby yogurts, snack puffs, and fruit purées in pouches

• Toddler “meal kits” or shelf-stable pasta dishes

• Boxed “kid foods” like mac-and-cheese, nuggets, and sweetened cereals

In short:
If it comes in a box, bag, or bottle with more than five ingredients—especially ones you wouldn’t cook with at home (maltodextrin, emulsifiers, colorings, hydrogenated oils, or flavorings)—it’s almost certainly ultra-processed.

Share

What is and Addiction

An Addiction is a state in which a person becomes physically or psychologically dependent on a substance or behavior, continuing to engage in it despite harm. It is not limited to drugs or alcohol; people can become addicted to food, social media, gambling, shopping, or even work. What defines addiction is not the object itself but the loss of control, craving, tolerance, and withdrawal when it is removed. In all forms, addiction hijacks the brain’s reward system, replacing balance and choice with compulsion and emotional dependence.

Addiction by Design

The term “ultra-processed food addiction” (UPFA) is now being used in serious scientific circles. The 2025 study found that 12.4% of U.S. adults over age 50 met addiction criteria using the Yale Food Addiction Scale—comparable to the national rates of alcohol or tobacco addiction.

Crucially, the highest rate was found in women aged 50–64 (21%), suggesting a lifelong imprint from the diet culture of the 1980s, when tobacco-owned food companies marketed “low-fat” but sugar-laden snacks to women under the guise of health and slimness. These companies pioneered the same strategies once used to sell cigarettes: hyper-palatable ingredients, colorful packaging, emotional advertising, and social normalization of consumption.

This is not a metaphorical addiction. People report intense cravings, loss of control, withdrawal, and continued use despite harm—just as in substance use disorders. The combination of refined carbohydrates and fats hijacks the brain’s dopamine system, creating a “reward loop” that overrides hunger and satiety cues.

Why This Matters for Women Trying to Conceive

For women planning pregnancy, this is not just a nutrition issue—it’s a fertility issue. Studies link high UPF intake with:

• Insulin resistance and inflammation, which disrupt ovulation and embryo implantation

• Altered gut microbiome, affecting hormone metabolism and nutrient absorption

• Increased oxidative stress, impairing egg quality

• Higher rates of obesity and gestational diabetes, both major causes of infertility and pregnancy complications

Even before conception, a diet dominated by UPFs can shift hormone signaling and reduce oocyte quality. During pregnancy, it can contribute to excessive gestational weight gain, gestational diabetes, and altered fetal programming—raising the baby’s lifetime risk of obesity and metabolic disease.

UPFs are calorie-rich but nutrient-poor. They flood the bloodstream with glucose and lipids, triggering repeated insulin spikes that destabilize hormonal balance. Over time, the same reward-seeking circuitry that drives overeating can blunt motivation to prepare wholesome meals, further reinforcing the cycle.

Why This Matters for Pregnant Women

During pregnancy, the effects of ultra-processed foods go beyond the mother’s metabolism—they extend to the developing baby. The placenta, which acts as the baby’s lifeline, is highly sensitive to changes in blood sugar, lipids, and inflammatory markers. Diets high in UPFs can lead to abnormal placental growth and impaired nutrient transport, which may increase the risk of fetal overgrowth or restricted growth depending on how the mother’s body responds. The same metabolic shifts that make these foods addictive can also alter hormone levels such as insulin, leptin, and cortisol, influencing how the baby’s metabolism is “set” for the future.

UPFs also displace essential nutrients critical in early pregnancy, including folate, iron, iodine, and omega-3 fatty acids, which are needed for neural tube formation and brain development. Many women who eat a diet dominated by processed foods appear well-nourished by calorie count but are, in fact, micronutrient deficient. This mismatch—too much energy but too few nutrients—creates a form of hidden malnutrition that can silently affect fetal growth and neurodevelopment.

Finally, pregnancy itself heightens sensitivity to addictive foods. Fluctuating hormones, emotional stress, and fatigue can amplify cravings for quick, sweet, or salty items. Understanding that these cravings are biologically reinforced, not simply a lack of willpower, helps reframe prenatal nutrition as both a medical and psychological challenge. Reducing UPFs is therefore not about perfection or dieting—it’s about protecting the shared physiology between mother and baby from an environment engineered to exploit human biology.

A New Clinical Language: Addiction, Not Weakness

Labeling this behavior “addiction” may seem strong—but it’s scientifically and ethically important. Calling it lack of willpower ignores the neurobiology. Women who struggle to stop eating chips, sweets, or fast food are not failing morally; they are facing a biologically conditioned compulsion.

Recognizing UPF addiction reframes the problem from shame to science. It also creates accountability for the food industry, which has long engineered these products for maximal “craveability.” The 2025 Addiction study confirms that people with UPF addiction have 2–4 times higher rates of poor physical and mental health and are three times more likely to feel socially isolated. Food addiction is therefore not just dietary—it’s psychological and social.

Fertility, Mood, and Metabolism: The Triple Intersection

Many women trying to conceive are also coping with anxiety or depression, conditions closely tied to UPF consumption. Emotional eating, mood swings, and body dissatisfaction are often intertwined. UPFs temporarily soothe distress but intensify guilt and fatigue afterward, perpetuating both mental health and metabolic imbalance.

Emerging evidence suggests that inflammation triggered by UPFs can influence serotonin pathways, making depression and infertility share a biological root. In other words, the same food environment that fuels obesity may also fuel despair and subfertility.

The New Preconception Counseling Imperative

Preconception visits must expand beyond folic acid and BMI checks. Clinicians should screen for UPF consumption patterns—soda, processed snacks, fast food frequency—and discuss food addiction openly, just as we counsel about alcohol or nicotine.

Practical steps include:

1. Name the problem: Explain that “food addiction” is a real, studied condition.

2. Spot the triggers: Encourage patients to read ingredient lists for “refined starch,” “hydrogenated oil,” or “flavoring.”

3. Gradual withdrawal: Replace one UPF per day with a whole-food equivalent.

4. Mind-gut reconnection: Mindful eating, regular meals, and gut-supporting foods (fiber, fermented items) can help reset appetite cues.

5. Emotional support: Referral to nutrition counseling or therapy if cravings or guilt dominate eating behavior.

For those with PCOS, obesity, or irregular cycles, targeting UPF reduction may be more effective for restoring fertility than aggressive weight loss programs alone.

The Ethical Dimension: Industry Accountability

The moral question isn’t just “Why can’t patients stop eating junk food?” but “Why were these products allowed to be designed to override self-control?” When tobacco companies entered the food market in the 1970s, they transferred decades of addiction science into snack engineering. Today, the legacy persists—only now the addiction is legal, ubiquitous, and socially normalized.

For women, this is particularly insidious. Many diet-branded UPFs were marketed as empowering and feminine—“guilt-free,” “light,” “lean cuisine.” Yet they delivered sugar highs and metabolic crashes that mimicked emotional dependence. This false promise of control may have deepened both physiological and psychological vulnerability.

My Take

Ultra-processed food addiction is not fringe science. It’s a public health crisis hiding in plain sight. For women preparing for pregnancy, it may be the single most modifiable determinant of reproductive and mental well-being.

We need obstetricians, reproductive endocrinologists, and dietitians to treat UPF addiction as seriously as any substance use disorder. Preconception and prenatal care should include nutritional neuroscience—how foods manipulate reward and hormones.

Medical societies must advocate for labeling, taxation, and advertising limits similar to tobacco control. And at the personal level, every meal is a chance to reclaim autonomy from a system designed to hijack it.

Reflection / Closing

If food can act like a drug, should physicians begin screening for “dietary addiction” the way we screen for smoking or alcohol use? And if our society knowingly engineers dependence through the supermarket, who truly bears the moral responsibility—the eater or the designer?

Donor screening in sperm and egg donation is designed to reduce risk, not to eliminate it. Modern genetic testing is far more extensive than it was even a decade ago, yet important uncertainties remain. Thousands of genetic conditions exist, many are incompletely understood, and some clinically serious risks cannot be detected with current testing. When donor gametes are used repeatedly, these unavoidable uncertainties are multiplied, changing their ethical significance.

The following prompts and checklists are intended to support transparent review of donor test results, clarify what has and has not been evaluated, and ensure that informed consent reflects real understanding rather than false reassurance. They are not meant to discourage donor conception, but to promote ethical clarity, accountability, and preventive responsibility in the face of uncertainty.

Donor Screening Checklist

What to Review Before Using Sperm or Egg Donation

This checklist helps you understand what donor testing means, what it does not mean, and what questions to ask before proceeding.

1. What testing WAS done

Check off what you have actual written results for, not just summaries.

☐ Infectious disease testing
☐ Genetic carrier screening (recessive childhood diseases)
☐ Chromosome testing (karyotype or similar)
☐ Medical history of the donor
☐ Family medical history
☐ Cancer-related genetic testing (if any)
☐ Other genetic panels (list them): ______________________

Important: Ask for a list of exact genes tested, not just “expanded panel.”

2. What each negative result really means

For each test, confirm that you understand:

☐ What the test is designed to find
☐ What a negative result rules out
☐ What it does not rule out
☐ Whether the test reduces risk a lot or only a little
☐ Whether the test can miss rare or new conditions

Key point: A negative test does not mean “no genetic risk.”

3. What is usually NOT tested

Ask directly whether testing included:

☐ Dominant cancer predisposition genes
☐ Conditions with adult onset
☐ Conditions with variable expression or incomplete penetrance
☐ Germline mosaicism (usually not detectable)
☐ Mitochondrial disorders (egg donors)

If not tested, ask: Why not, and what does that mean for risk?

4. Timing matters

☐ How old are these test results?
☐ Were newer or broader tests developed since then?
☐ Would repeating or expanding testing today change anything meaningful?

Older tests may still be valid, but you should know their limits.

5. How donor screening compares to natural conception

Understand this clearly:

☐ Most biological parents are not screened for cancer genes
☐ Donor screening is often more extensive, but still incomplete
☐ Donor screening reduces risk, it does not eliminate it

This is about risk reduction, not certainty.

6. Scale matters ethically

Ask and document:

☐ How many families has this donor already been used for?
☐ In how many countries or clinics?
☐ Are there limits, and who enforces them?

Important: A rare risk becomes more likely when repeated many times.

7. What you should be told, ethically

You deserve to know:

☐ What is known
☐ What is unknown
☐ What cannot be known with current science
☐ Where uncertainty still exists

If something is uncertain, it should be stated clearly.

8. Questions to ask before proceeding

☐ What risks remain even with all current testing?
☐ Which risks cannot be reduced by more testing?
☐ Are there risks that increase because this donor is used many times?
☐ What happens if a new problem is discovered years from now?

9. Red flags to notice

Be cautious if you hear:

☐ “This donor is completely safe”
☐ “Everything has been tested”
☐ “There is nothing to worry about”
☐ “This is extremely rare, so it doesn’t matter”

Ethical counseling explains limits. Marketing minimizes them.

10. Bottom line to remember

☐ Screening reduces risk but never removes it
☐ Genetics is probabilistic, not certain
☐ The biggest ethical risk is scale, not testing failure
☐ Honest uncertainty is safer than false reassurance

If you want:
This checklist can be reviewed with a genetic counselor or physician who is willing to discuss uncertainty openly, not just results.

PROMPTS

How to Use These Prompts

These prompts are designed to help prospective recipients and clinicians critically review donor screening results, rather than assume that screening equals safety. Donor testing reduces risk, but it does not remove uncertainty, and important genetic risks may remain even when all standard requirements are met. To use the prompts, first obtain complete copies of all donor test reports, not summaries or profiles. Then paste the results verbatim and in full into the prompt, including laboratory names, dates, and gene lists if available. The prompt should be run without paraphrasing or omission, and the output reviewed slowly, focusing on what each test does and does not rule out, which risks remain, and where uncertainty persists. The goal is not reassurance or decision-making by the tool itself, but clarity. These prompts are most effective when their output is reviewed with a clinician or genetic counselor who is willing to discuss limits openly and document informed consent that reflects understanding, not assumption.

I acknowledge that donor screening is intended to reduce, but cannot eliminate, genetic and medical risks. I understand that current testing does not detect all conditions, including rare, de novo, or mosaic genetic variants, and that scientific knowledge and testing capabilities are inherently limited and may evolve over time. I further understand that the use of donor gametes may involve risks that cannot be fully predicted or prevented, including risks that may become apparent only after conception or birth, and that my decision is made with awareness of these limitations and uncertainties.

PROMPT 1: Comprehensive Review of Sperm Donor Screening Results

You are acting as a reproductive genetics consultant and clinical ethicist with expertise in sperm donation, donor screening standards, population risk amplification, and ethical risk disclosure.

I will provide you with all available medical, genetic, and laboratory test results from a prospective sperm donor.

YOUR TASKS

1. Inventory and Classification

Create a complete inventory of all tests performed.
For each test, state clearly:

• Test name

• Category (infectious disease, carrier screening, chromosomal analysis, targeted gene testing, sequencing panel)

• Specimen type (blood, semen, saliva)

• Date performed

• Laboratory and testing methodology, if available

• Whether the test is screening or diagnostic

Present this in a structured table.

2. Interpretation of Each Result

For each test, explain in plain, precise language:

• What the test is designed to detect

• What a normal or negative result means

• What it does not rule out

• Known limitations, including false negatives and biological constraints

• Whether the result meaningfully reduces reproductive risk or only partially addresses it

Avoid vague reassurance. Quantify or contextualize risk whenever possible.

3. Male-Specific Genetic and Biological Risks

Address risks particularly relevant to sperm donation:

• Autosomal recessive carrier status

• Autosomal dominant conditions

• X-linked conditions transmitted to female offspring

• Germline mosaicism, including why semen-based risk may differ from blood testing

• Cancer predisposition syndromes with incomplete penetrance

Explicitly state which of these were evaluated, partially evaluated, or not evaluated.

4. Missing or Incomplete Testing

Identify all relevant gaps, including but not limited to:

• Dominant cancer predisposition genes, if not tested

• Conditions that cannot be detected by blood testing alone

• Mosaic mutations affecting sperm

• Age-related mutational risk, if applicable

• Limits of family history–based screening

List missing elements explicitly.

5. Temporal Relevance

Assess:

• Whether tests are outdated by current standards

• Whether expanded panels now exist that were not available at testing

• Whether re-testing would materially change risk understanding

6. Comparison to Natural Conception

Explain how this donor’s screening compares with:

• Typical screening of biological fathers in natural conception

• Routine partner screening in obstetric practice

Clarify where donor screening is more extensive and where it is not.

7. Scale and Risk Amplification

Explain how residual genetic uncertainty changes when:

• One sperm donor is used once

• The same donor is used repeatedly across many families and countries

Emphasize that scale transforms probability into foreseeable harm.

8. Ethical Transparency Check

Answer directly:

• Would a reasonable recipient overestimate safety based on these results?

• Are there risks that are ethically significant but scientifically unavoidable?

• Is uncertainty being minimized by presentation rather than explained?

9. Recommendations

Provide three lists:

1. Tests that should strongly be considered adding, with justification

2. Tests that would add little value, and why

3. Risks that cannot be meaningfully reduced by additional testing

10. Plain-Language Summary

Summarize for a non-medical reader:

• What is known

• What remains unknown

• What cannot be known

• Where the greatest remaining risks lie, especially due to scale

CRITICAL CONSTRAINTS

• Do not equate negative tests with safety

• Do not minimize uncertainty

• Distinguish scientific limits from ethical decisions

• State clearly when evidence is insufficient

INPUT INSTRUCTIONS

After this prompt, I will paste all donor test results and documentation.
Wait for that information before proceeding.

PROMPT 2: Comprehensive Review of Egg Donor Screening Results

You are acting as a reproductive genetics consultant and clinical ethicist with expertise in egg donation, maternal-effect genetics, mitochondrial inheritance, and donor screening ethics.

I will provide all available medical, genetic, and laboratory test results from a prospective egg donor.

YOUR TASKS

1. Inventory and Classification

Create a complete inventory of all tests performed.
For each test, state:

• Test name

• Category (infectious disease, carrier screening, chromosomal analysis, sequencing panel, reproductive health assessment)

• Specimen type (blood, saliva, other)

• Date performed

• Laboratory and testing methodology

• Whether the test is screening or diagnostic

Present this in a structured table.

2. Interpretation of Each Result

For each test, explain clearly:

• What the test detects

• What a negative or normal result means

• What it does not exclude

• Test limitations, including penetrance and expression variability

• Whether the result reduces risk for offspring or primarily informs donor health

Avoid reassurance language.

3. Female-Specific Genetic and Biological Risks

Address risks unique or especially relevant to egg donation:

• Autosomal recessive carrier status

• Autosomal dominant conditions

• X-linked inheritance

• Mitochondrial DNA disorders

• Conditions influenced by maternal genetic contribution beyond nuclear DNA

• Cancer predisposition syndromes relevant to female carriers

State explicitly what was and was not evaluated.

4. Missing or Incomplete Testing

Identify gaps including:

• Mitochondrial genome assessment, if absent

• Dominant adult-onset conditions

• Conditions with incomplete penetrance

• Structural chromosomal issues beyond standard karyotype

• Limits of family history screening

List missing elements explicitly.

5. Temporal Relevance

Assess:

• Whether testing reflects current standards

• Whether newer panels or methodologies would add meaningful insight

• Whether repeat testing would materially change understanding

6. Comparison to Natural Conception

Explain how this donor’s screening compares with:

• Typical screening of women conceiving naturally

• Standard prenatal genetic screening practices

Clarify where donor screening exceeds routine care and where it does not.

7. Scale and Reproductive Impact

Explain how uncertainty changes when:

• One egg donation results in one child

• The same donor’s eggs result in multiple children over time

Discuss scale even when absolute numbers are smaller than sperm donation.

8. Ethical Transparency Check

Answer directly:

• Would recipients likely assume greater certainty than justified?

• Are important risks ethically relevant but scientifically unavoidable?

• Is donor health screening being conflated with offspring safety?

9. Recommendations

Provide:

1. Tests that should strongly be considered adding, with rationale

2. Tests that would add little value, with explanation

3. Areas where no testing can meaningfully reduce uncertainty

10. Plain-Language Summary

End with a non-technical explanation of:

• What is known

• What is unknown

• What cannot be known

• What risks remain despite extensive screening

CRITICAL CONSTRAINTS

• Do not assume negative tests equal safety

• Do not minimize uncertainty

• Separate maternal health screening from offspring risk

• State clearly when evidence is incomplete

INPUT INSTRUCTIONS

After this prompt, I will paste all egg donor test results and documentation.
Wait for that information before proceeding.

Below is a clinic-facing, one-page checklist intended for fertility clinics, reproductive endocrinologists, donor programs, and genetic counselors.
It is written to support ethical compliance, transparency, and defensibility, not marketing or reassurance.

Donor Screening Transparency Checklist

Clinic Version – Sperm and Egg Donation

Purpose:
To ensure donor screening, counseling, and documentation meet not only regulatory requirements but also ethical standards for informed consent under uncertainty.

1. Documentation completeness

Confirm that the medical record contains:

☐ Original laboratory reports, not summaries
☐ Dates of all tests
☐ Names of laboratories and methodologies
☐ Gene lists for all genetic panels
☐ Clear distinction between screening vs diagnostic testing

Do not rely on marketing summaries or donor profiles alone.

2. Screening categories reviewed

Confirm that the following categories were explicitly addressed and documented:

☐ Infectious disease screening (per regulatory requirements)
☐ Medical history and physical assessment
☐ Family history, including cancer history
☐ Autosomal recessive carrier screening
☐ Autosomal dominant conditions, if tested
☐ X-linked conditions
☐ Chromosomal analysis (karyotype or equivalent)
☐ Additional testing specific to sperm or egg donation

3. Explicit limitations documented

Ensure the consent record includes acknowledgment that:

☐ Negative results do not eliminate genetic risk
☐ Rare conditions and de novo mutations may not be detected
☐ Germline mosaicism cannot be reliably excluded
☐ Penetrance and expression are variable and unpredictable
☐ Scientific knowledge evolves over time

Absence of this language creates ethical and legal vulnerability.

4. Sex-specific risk disclosure

For sperm donation:

☐ Germline mosaicism discussed
☐ Scale-dependent risk explained
☐ X-linked transmission addressed
☐ Age-related mutational risk, if relevant

For egg donation:

☐ Mitochondrial inheritance discussed
☐ Maternal-effect genetics clarified
☐ Female-specific cancer predisposition risks addressed
☐ Distinction made between donor health screening and offspring risk

5. Scale and distribution transparency

Document that recipients were informed of:

☐ Number of families already using the donor
☐ Geographic distribution, if international
☐ National or clinic-specific limits
☐ Absence of international caps, if applicable

Scale must be treated as an ethical variable, not an administrative detail.

6. Temporal relevance assessment

Confirm that counseling addressed:

☐ Age of genetic testing
☐ Whether newer panels now exist
☐ Whether re-testing would materially change risk assessment
☐ Limits of retrospective reinterpretation

7. Comparison to natural conception clarified

Ensure recipients were told that:

☐ Most biological parents are not screened for cancer genes
☐ Donor screening is more extensive than routine care, but incomplete
☐ Donor screening reduces risk, it does not guarantee safety

This prevents false assumptions of genetic certainty.

8. Language audit

Review counseling language for the following red flags:

☐ “Completely screened”
☐ “Genetically safe”
☐ “Everything was tested”
☐ “No remaining risk”

Replace with language that accurately reflects uncertainty.

9. Ethical consent confirmation

Before proceeding, confirm that:

☐ Uncertainty was discussed, not minimized
☐ Missing tests were disclosed
☐ Limits of screening were explained
☐ Consent reflects understanding, not just signature

10. Record defensibility check

Ask internally:

☐ Would this consent withstand review years later after an adverse outcome?
☐ Is uncertainty documented as clearly as testing?
☐ Is scale-related risk explicitly acknowledged?

If not, consent is ethically incomplete.

Ethical bottom line for clinics

Donor screening is a risk-reduction strategy, not a guarantee.
Ethical practice requires that clinics disclose not only what was tested, but also what could not be tested and why that matters at scale.

Subscribe now

As an obstetrician and MFM specialist, I must categorically reject the idea that expanding in vitro fertilization (IVF) access, without fixing our broken maternal care system, represents progress.

The United States has the highest maternal mortality rate among developed nations—and it is still rising. Promoting more pregnancies without first securing safe systems for childbirth is not compassion. It is negligence at scale.

Every year, hundreds of women in the United States die from pregnancy-related causes that should never occur in a wealthy nation. Hemorrhage, preeclampsia, infection, and cardiovascular complications remain leading culprits, but behind these medical terms lies a deeper failure: a disintegrating safety infrastructure. Labor units are closing across rural America. Postpartum care remains an afterthought. Racial disparities are widening. Yet the latest political headlines celebrate efforts to “expand access to IVF” as if that alone constitutes progress in women’s health.

IVF is an extraordinary scientific achievement. It has helped millions of families conceive. But it is also a medical intervention that carries higher risks than spontaneous conception.

Women who conceive through IVF are significantly more likely to develop preeclampsia, placenta previa, postpartum hemorrhage, and to deliver preterm or by cesarean section. These risks increase further with advanced maternal age and multiple gestations—both more common in IVF patients. To expand IVF access without simultaneously strengthening obstetric safety systems is to invite predictable tragedy.

In ethics, context is everything. When a system is already failing to protect mothers, encouraging more high-risk pregnancies becomes morally indefensible. The policy calculus here is not neutral: it shifts risk downward onto women while shifting political credit upward to those who claim to be “pro-family.” This is not family building. It is political theater staged on the bodies of pregnant women.

The contradiction deepens when viewed against the backdrop of the Dobbs decision and its aftermath.

The same political movement now claiming to “support IVF and fertility care” has spent the past two years dismantling reproductive rights. State abortion bans have criminalized physicians, delayed lifesaving care, and endangered women with ectopic pregnancies, sepsis, and miscarriages. The Alabama Supreme Court’s 2024 ruling—declaring frozen embryos to be legally equivalent to children—shows how this ideology collapses under its own weight. IVF inherently involves the creation, freezing, and often the discarding of embryos. Declaring embryos “persons” makes IVF legally precarious, if not impossible.

This is not an abstract ethical puzzle. It is a direct consequence of selective moral reasoning. A government cannot credibly promote IVF while simultaneously endorsing embryo personhood laws that criminalize the very process. The ethical contradiction is staggering.

The rhetoric of “lowering costs” adds insult to injury. Without insurance mandates, federal subsidies, or Medicaid coverage, IVF remains financially out of reach for most families. One cycle averages over $15,000 and may need to be repeated several times. Claiming affordability while refusing to fund it is like promising universal education while shuttering public schools. It sounds compassionate but functions as exclusion. Fertility care remains the privilege of the insured and affluent, while millions of women lack access to even basic prenatal care.

If policymakers truly cared about family building, they would start where families actually struggle: with maternal safety, economic stability, and postpartum support. They would ensure every hospital that delivers babies has 24/7 obstetric coverage, blood banking, and rapid response teams. They would fund community-based doulas and midwives, especially in underserved areas. They would guarantee paid parental leave, mental health services, and access to contraception and abortion. Those are the foundations of reproductive freedom and family health.

Instead, we are witnessing the rise of selective pronatalism—a moralized push for more births, detached from any commitment to maternal survival or autonomy. It is the same logic that drives abortion bans and opposes contraception access: an obsession with pregnancy as a moral outcome rather than a medical event. But ethics demands coherence. You cannot claim to value life while ignoring the lives of the women who create it.

In medicine, “first, do no harm” applies not only to individuals but to systems. Expanding high-risk pregnancies without expanding safety is harm. Encouraging IVF in states where pregnant women cannot obtain emergency abortions is harm. Using women’s fertility as a political prop while refusing to invest in maternal health is harm.

The ethical obligation of physicians is to resist policies that endanger patients, even when cloaked in the language of “family values.” Our duty is to truth, safety, and compassion—not to ideology.

Reflection / Closing:
Ethics without empathy is manipulation. Policy without safety is malpractice. If America truly wishes to support families, it must first protect mothers. More pregnancies without more safety means more deaths, not more life. Until maternal survival is treated as a non-negotiable national priority, every political celebration of “fertility expansion” remains an empty gesture—dangerous, dishonest, and profoundly unethical.

When Sarah came to see me at age 34, she was healthy, active, and eager to start a family. She had regular cycles, no medical issues, and assumed getting pregnant would be easy. What she didn’t know—and what so many women and couples don’t realize—is that the quality of a woman’s eggs is the single most important factor in fertility.

Subscribe now

Fertility and the Role of Eggs

Every woman is born with all the eggs she will ever have. Unlike sperm, which are produced daily throughout a man’s life, egg supply steadily declines from birth until menopause. But it’s not only the number of eggs that matters—it’s their quality.

A “good egg” contains the right number of chromosomes and healthy mitochondria (the energy factories inside cells). This makes it much more likely to fertilize, develop into a healthy embryo, and result in a live birth. A “bad egg,” by contrast, may have chromosomal errors, damaged DNA, or weak energy reserves. These eggs either fail to fertilize, fail to implant, or result in early miscarriage.

Age and Egg Quality

Age is the most powerful influence on egg quality. At age 20, about 80–90% of a woman’s eggs are chromosomally normal. By age 35, that percentage drops to about 50%. By 40, only about 10–20% of eggs are normal. This explains why fertility treatments such as IVF have much higher success rates in younger women, even when using the same protocols.

This decline is a biological reality—not something you can control with diet or supplements. While healthy living helps overall fertility, it cannot turn an abnormal egg into a normal one.

Can We Test Egg Quality?

This is where things often get confusing for patients. Doctors can measure egg quantity—but not egg quality—with current tests. Blood work such as AMH (Anti-Müllerian Hormone) or day-3 FSH, along with ultrasound antral follicle counts, are widely used in fertility clinics. They can estimate how many eggs remain, but they say little about whether those eggs are healthy.

AMH in particular has been marketed as a kind of fertility crystal ball, even sold directly to consumers. But it’s not fool-proof. A high AMH does not guarantee good eggs or pregnancy success, and a low AMH does not mean you cannot conceive. It only reflects the size of the ovarian reserve, not the genetic integrity of the eggs.

Consider two examples:

• A 30-year-old with a low AMH may still have mostly chromosomally normal eggs, meaning her chance of pregnancy per egg is high.

• A 42-year-old with a normal AMH may still face a high percentage of abnormal eggs simply because of age.

The critical point: egg quality is driven far more by age than by lab results. Even with all our modern technology, the only way to truly observe egg quality is indirectly—through fertilization, embryo development, and sometimes genetic testing of embryos in the IVF lab.

For prospective parents, this means two things:

1. Do not panic if your AMH is “low”—it does not mean zero chance.

2. Do not feel falsely reassured if your AMH is “normal”—it does not cancel out the effect of age.

In short, AMH is a useful tool for guiding fertility treatments, especially IVF stimulation, but it is not a fertility predictor for natural conception. Relying too heavily on the number can cause unnecessary anxiety—or false confidence.

Share

Polycystic Ovary Syndrome (PCOS)

What it is:
Polycystic Ovary Syndrome, or PCOS, is a hormonal condition that affects about 1 in 10 women of reproductive age. It’s characterized by irregular menstrual cycles, higher levels of male-type hormones (androgens), and ovaries that often appear “polycystic” on ultrasound—meaning they contain many small, immature follicles.

How it affects eggs and fertility:
Women with PCOS typically have a large number of eggs—in fact, their AMH levels are usually higher than average. But the challenge lies in how those eggs mature and are released. Many women with PCOS do not ovulate regularly. When ovulation does occur, the egg may not be fully mature, which reduces the chance of successful fertilization.

Importantly, PCOS does not inherently damage the eggs. When a healthy, mature egg is released, its quality is generally the same as that of women without PCOS at the same age. The main barrier is irregular or absent ovulation.

What can be done:
Treatments often focus on restoring regular ovulation. This may include lifestyle changes such as weight management, medications like letrozole or clomiphene, and sometimes injectable fertility drugs. With the right approach, most women with PCOS can conceive, though it may take longer and require medical support.

Premature Ovarian Insufficiency (POI)

What it is:
Premature Ovarian Insufficiency (POI), formerly called premature ovarian failure, is a condition where the ovaries lose their normal function before age 40. It affects about 1% of women. Unlike natural menopause, which occurs on average around age 51, POI happens much earlier—sometimes in the teens, 20s, or 30s.

How it affects eggs and fertility:
Women with POI have a very low number of eggs remaining. Periods may become irregular or stop altogether. Estrogen levels often fall, leading to symptoms similar to menopause, such as hot flashes and bone loss. Fertility is usually severely reduced because so few eggs are left.

Unlike PCOS, the issue here is not too many eggs stuck in immature stages, but rather too few eggs overall. Egg quality may be normal for the woman’s age, but scarcity makes conception difficult. A small percentage of women with POI may still ovulate occasionally and conceive naturally, but this is rare.

What can be done:
Hormone replacement therapy is important for bone and heart health. For family-building, most women with POI require donor eggs if they wish to carry a pregnancy. Genetic counseling may also be helpful, since some cases are linked to inherited conditions.

Lifestyle and “Egg Health”

While age sets the baseline, lifestyle factors can make a difference. Smoking, obesity, and poorly controlled medical conditions like diabetes harm eggs. Excessive alcohol and environmental toxins may also play a role. On the flip side, maintaining a healthy weight, eating a balanced diet, exercising moderately, and taking a prenatal vitamin with folic acid support fertility overall.

Some studies suggest that antioxidants, vitamin D, or supplements like CoQ10 may help egg energy production, but evidence is limited. None of these can reverse age-related changes.

Options for Parents

Understanding egg quality helps prospective parents make realistic choices:

• Younger couples trying to conceive naturally can be reassured that most eggs are good and patience is often all that’s needed.

• Couples in their mid- to late-30s may want to seek evaluation sooner if pregnancy doesn’t occur within 6 months.

• Women in their 40s may need to consider assisted reproduction, donor eggs, or alternative family-building options. Donor eggs, from younger women, carry dramatically higher success rates because of their better quality.

The Emotional Side

Talking about “good eggs” and “bad eggs” can feel harsh. Many patients worry it sounds like a judgment about them. It’s not. Egg quality is biology, not character. And while the concept may seem discouraging, knowledge empowers couples to plan ahead, explore options early, and avoid wasted time or unnecessary guilt.

Closing Reflection

When Sarah learned that egg quality—not just quantity—was the key factor, she and her partner made informed choices sooner rather than later. She became pregnant after two IVF cycles, and she told me later: “I wish I had known this earlier.”

The reality is simple but profound: women cannot make new eggs, and age affects egg quality more than any other factor. Should society do more to educate young people about this reality—long before they are in my office, worried about their chances?